Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Lixte Biotechnology Holdings ( (LIXT) ).
On July 15, 2025, Lixte Biotechnology Holdings, Inc. announced that it regained compliance with Nasdaq’s Listing Rule 5550(b)(1), following a $5.0 million placement and a $1.5 million registered direct offering earlier in July. This compliance underscores the company’s commitment to maintaining its Nasdaq listing and enhancing its financial health, as it continues to advance its clinical trials in cancer treatment.
More about Lixte Biotechnology Holdings
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies. The company is pioneering a new field of cancer biology with its lead compound, LB-100, a PP2A inhibitor, which has shown potential to enhance chemotherapies and immunotherapies. LIXTE is conducting proof-of-concept clinical trials for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma.
Average Trading Volume: 2,103,346
Technical Sentiment Signal: Hold
Current Market Cap: $9.55M
See more data about LIXT stock on TipRanks’ Stock Analysis page.